External organizationBoehringer Ingelheim Pharma GmbH & Co. KG

Basic data

Name:

Boehringer Ingelheim Pharma GmbH & Co. KG

Country:

Germany

Region/province:

Rheinland-Pfalz

City:

Ingelheim am Rhein

URL:

www.boehringer-ingelheim.de

Projects

A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy

2015 - 2018

Boehringer Ingelheim Pharma GmbH & Co. KG

2017 - 2023

Boehringer Ingelheim Pharma GmbH & Co. KG

BI2017 – Identification of novel cancer antigens based on integration of different methods

2017 - 2019

Boehringer Ingelheim Pharma GmbH & Co. KG

Klinische Studie

2016 - 2018

Boehringer Ingelheim Pharma GmbH & Co. KG

2016 - 2018

Boehringer Ingelheim Pharma GmbH & Co. KG

Studie Böhringer Ingelheim BI1399-0003 Balance

2020

Boehringer Ingelheim Pharma GmbH & Co. KG

Help

will be deleted permanently. This cannot be undone.